

PEER-REVIEW REPORT

Name of journal: World Journal of Diabetes

Manuscript NO: 58684

Title: GLP-1RA and SGLT-2i combination - are we exploiting their full potential in a real life setting

Reviewer's code: 05040445

Position: Editorial Board

Academic degree: MD, PhD

Professional title: Associate Professor

Reviewer's Country/Territory: China

Author's Country/Territory: Croatia

Manuscript submission date: 2020-08-13

Reviewer chosen by: AI Technique

Reviewer accepted review: 2020-08-13 21:22

Reviewer performed review: 2020-08-17 18:29

Review time: 3 Days and 21 Hours

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input checked="" type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input checked="" type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
Peer-reviewer statements	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No

SPECIFIC COMMENTS TO AUTHORS

The author aim was to investigate the efficacy of simultaneous versus sequential initiation approach of GLP-1RA and SGLT-2i combination in real world setting. It is kind of interesting, however, much has to be done to make the manu more readable. 1. If the author want to compare the efficacy of simultaneous versus sequential initiation approach of GLP-1RA and SGLT-2i, then, Table 1 should be comparison of the baseline characteristics of the three group, including HbA1c, FBG,PPG, blood lipids, eGFR, blood pressure, diabetic duration, BMI etc. 2. Because of many patients has a long duration, so what about anti-diabetic drugs did those patients use before the initiation of GLP-1RA and SGLT-2i? 3. Did they have other complications? Did they use anti-hypertensive drugs or anti- hyperlipidemia drugs? what about the ratio in each group? did they have any differences? 4. Except for ANOVA test, what about the differences between any two groups? 5. What about the adverse effects of the drugs in each group? 6. What about the changes of blood pressure?